| Melissa Marie Hurst, MD | |
|
2120 W Elk Ave, Duncan, OK 73533-1569 | |
| (580) 251-6822 | |
| Not Available |
| Full Name | Melissa Marie Hurst |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 12 Years |
| Location | 2120 W Elk Ave, Duncan, Oklahoma |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1679834345 | NPI | - | NPPES |
| 200442590A | Medicaid | OK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 29349 (Oklahoma) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Health Watch Health Care Of Duncan, Llc | Duncan, OK | Home health agency |
| Duncan Regional Hospital Homecare | Duncan, OK | Home health agency |
| Genesis Healthcare,llc | Durant, OK | Home health agency |
| Elara Caring Iv | Chickasha, OK | Home health agency |
| Complete Home Health Of Tishomingo Llc | Tishomingo, OK | Home health agency |
| Duncan Regional Hospital, Inc | Duncan, OK | Hospital |
| Jefferson County Hospital | Waurika, OK | Hospital |
| Wilkins Health & Rehabilitation Community | Duncan, OK | Nursing home |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Duncan Regional Hospital, Inc. | 5193613057 | 31 |
| Hcc Duncan Inc | 1759447873 | 8 |
| Solutions Practice Management | 5698840775 | 33 |
News Archive
Janssen-Cilag International NV (Janssen) announced today it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ibrutinib for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) or relapsed or refractory mantle cell lymphoma (MCL), two forms of blood cancer.
Life-threatening heart damage is an adverse side effect of the cancer drug doxorubicin, damage that also limits the use of newer chemotherapeutic agents such as trastuzumab and imatinib. The ability to protect the heart from these side effects would benefit patients, including cancer survivors who are at risk of developing heart damage years later, and it also could allow safer use of these drugs at higher doses.
Using data from the national register in Denmark, researchers studied how likely persons infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmit it within their households. The study found additional household members tested positive in 17% of cases after one person in the household was infected. The research is published on the preprint server medRxiv in September 2020.
It's the gift that keeps on giving, from early fall, through the holiday season and into late spring. It's seasonal flu, caused by a virus that can fly through the air, hitch a ride on a handshake, hug or kiss, and is extremely good at infecting people and making them sick.
Ductal carcinoma in situ (DCIS), the most common non-invasive lesion of the breast, presents unique challenges for patients and providers largely because the natural course of the untreated disease is not well understood. Because most women diagnosed with DCIS are treated, it is difficult to determine the comparative benefits of different treatment strategies versus active surveillance, meaning systematic followup.
› Verified 4 days ago
| Entity Name | Purcell Municipal Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467476911 PECOS PAC ID: 7719899400 Enrollment ID: O20031106000100 |
News Archive
Janssen-Cilag International NV (Janssen) announced today it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ibrutinib for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) or relapsed or refractory mantle cell lymphoma (MCL), two forms of blood cancer.
Life-threatening heart damage is an adverse side effect of the cancer drug doxorubicin, damage that also limits the use of newer chemotherapeutic agents such as trastuzumab and imatinib. The ability to protect the heart from these side effects would benefit patients, including cancer survivors who are at risk of developing heart damage years later, and it also could allow safer use of these drugs at higher doses.
Using data from the national register in Denmark, researchers studied how likely persons infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmit it within their households. The study found additional household members tested positive in 17% of cases after one person in the household was infected. The research is published on the preprint server medRxiv in September 2020.
It's the gift that keeps on giving, from early fall, through the holiday season and into late spring. It's seasonal flu, caused by a virus that can fly through the air, hitch a ride on a handshake, hug or kiss, and is extremely good at infecting people and making them sick.
Ductal carcinoma in situ (DCIS), the most common non-invasive lesion of the breast, presents unique challenges for patients and providers largely because the natural course of the untreated disease is not well understood. Because most women diagnosed with DCIS are treated, it is difficult to determine the comparative benefits of different treatment strategies versus active surveillance, meaning systematic followup.
› Verified 4 days ago
| Entity Name | Solutions Practice Management |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104009299 PECOS PAC ID: 5698840775 Enrollment ID: O20081015000361 |
News Archive
Janssen-Cilag International NV (Janssen) announced today it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ibrutinib for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) or relapsed or refractory mantle cell lymphoma (MCL), two forms of blood cancer.
Life-threatening heart damage is an adverse side effect of the cancer drug doxorubicin, damage that also limits the use of newer chemotherapeutic agents such as trastuzumab and imatinib. The ability to protect the heart from these side effects would benefit patients, including cancer survivors who are at risk of developing heart damage years later, and it also could allow safer use of these drugs at higher doses.
Using data from the national register in Denmark, researchers studied how likely persons infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmit it within their households. The study found additional household members tested positive in 17% of cases after one person in the household was infected. The research is published on the preprint server medRxiv in September 2020.
It's the gift that keeps on giving, from early fall, through the holiday season and into late spring. It's seasonal flu, caused by a virus that can fly through the air, hitch a ride on a handshake, hug or kiss, and is extremely good at infecting people and making them sick.
Ductal carcinoma in situ (DCIS), the most common non-invasive lesion of the breast, presents unique challenges for patients and providers largely because the natural course of the untreated disease is not well understood. Because most women diagnosed with DCIS are treated, it is difficult to determine the comparative benefits of different treatment strategies versus active surveillance, meaning systematic followup.
› Verified 4 days ago
| Entity Name | Hcc Duncan Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013153543 PECOS PAC ID: 1759447873 Enrollment ID: O20090225000497 |
News Archive
Janssen-Cilag International NV (Janssen) announced today it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ibrutinib for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) or relapsed or refractory mantle cell lymphoma (MCL), two forms of blood cancer.
Life-threatening heart damage is an adverse side effect of the cancer drug doxorubicin, damage that also limits the use of newer chemotherapeutic agents such as trastuzumab and imatinib. The ability to protect the heart from these side effects would benefit patients, including cancer survivors who are at risk of developing heart damage years later, and it also could allow safer use of these drugs at higher doses.
Using data from the national register in Denmark, researchers studied how likely persons infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmit it within their households. The study found additional household members tested positive in 17% of cases after one person in the household was infected. The research is published on the preprint server medRxiv in September 2020.
It's the gift that keeps on giving, from early fall, through the holiday season and into late spring. It's seasonal flu, caused by a virus that can fly through the air, hitch a ride on a handshake, hug or kiss, and is extremely good at infecting people and making them sick.
Ductal carcinoma in situ (DCIS), the most common non-invasive lesion of the breast, presents unique challenges for patients and providers largely because the natural course of the untreated disease is not well understood. Because most women diagnosed with DCIS are treated, it is difficult to determine the comparative benefits of different treatment strategies versus active surveillance, meaning systematic followup.
› Verified 4 days ago
| Entity Name | Duncan Regional Hospital, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699318147 PECOS PAC ID: 5193613057 Enrollment ID: O20200930003440 |
News Archive
Janssen-Cilag International NV (Janssen) announced today it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ibrutinib for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) or relapsed or refractory mantle cell lymphoma (MCL), two forms of blood cancer.
Life-threatening heart damage is an adverse side effect of the cancer drug doxorubicin, damage that also limits the use of newer chemotherapeutic agents such as trastuzumab and imatinib. The ability to protect the heart from these side effects would benefit patients, including cancer survivors who are at risk of developing heart damage years later, and it also could allow safer use of these drugs at higher doses.
Using data from the national register in Denmark, researchers studied how likely persons infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmit it within their households. The study found additional household members tested positive in 17% of cases after one person in the household was infected. The research is published on the preprint server medRxiv in September 2020.
It's the gift that keeps on giving, from early fall, through the holiday season and into late spring. It's seasonal flu, caused by a virus that can fly through the air, hitch a ride on a handshake, hug or kiss, and is extremely good at infecting people and making them sick.
Ductal carcinoma in situ (DCIS), the most common non-invasive lesion of the breast, presents unique challenges for patients and providers largely because the natural course of the untreated disease is not well understood. Because most women diagnosed with DCIS are treated, it is difficult to determine the comparative benefits of different treatment strategies versus active surveillance, meaning systematic followup.
› Verified 4 days ago
| Entity Name | Duncan Regional Hospital, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942918214 PECOS PAC ID: 5193613057 Enrollment ID: O20230701000000 |
News Archive
Janssen-Cilag International NV (Janssen) announced today it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ibrutinib for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) or relapsed or refractory mantle cell lymphoma (MCL), two forms of blood cancer.
Life-threatening heart damage is an adverse side effect of the cancer drug doxorubicin, damage that also limits the use of newer chemotherapeutic agents such as trastuzumab and imatinib. The ability to protect the heart from these side effects would benefit patients, including cancer survivors who are at risk of developing heart damage years later, and it also could allow safer use of these drugs at higher doses.
Using data from the national register in Denmark, researchers studied how likely persons infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmit it within their households. The study found additional household members tested positive in 17% of cases after one person in the household was infected. The research is published on the preprint server medRxiv in September 2020.
It's the gift that keeps on giving, from early fall, through the holiday season and into late spring. It's seasonal flu, caused by a virus that can fly through the air, hitch a ride on a handshake, hug or kiss, and is extremely good at infecting people and making them sick.
Ductal carcinoma in situ (DCIS), the most common non-invasive lesion of the breast, presents unique challenges for patients and providers largely because the natural course of the untreated disease is not well understood. Because most women diagnosed with DCIS are treated, it is difficult to determine the comparative benefits of different treatment strategies versus active surveillance, meaning systematic followup.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Melissa Marie Hurst, MD 1334 N Harville Rd, Duncan, OK 73533-1514 Ph: (580) 255-8564 | Melissa Marie Hurst, MD 2120 W Elk Ave, Duncan, OK 73533-1569 Ph: (580) 251-6822 |
News Archive
Janssen-Cilag International NV (Janssen) announced today it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ibrutinib for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) or relapsed or refractory mantle cell lymphoma (MCL), two forms of blood cancer.
Life-threatening heart damage is an adverse side effect of the cancer drug doxorubicin, damage that also limits the use of newer chemotherapeutic agents such as trastuzumab and imatinib. The ability to protect the heart from these side effects would benefit patients, including cancer survivors who are at risk of developing heart damage years later, and it also could allow safer use of these drugs at higher doses.
Using data from the national register in Denmark, researchers studied how likely persons infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmit it within their households. The study found additional household members tested positive in 17% of cases after one person in the household was infected. The research is published on the preprint server medRxiv in September 2020.
It's the gift that keeps on giving, from early fall, through the holiday season and into late spring. It's seasonal flu, caused by a virus that can fly through the air, hitch a ride on a handshake, hug or kiss, and is extremely good at infecting people and making them sick.
Ductal carcinoma in situ (DCIS), the most common non-invasive lesion of the breast, presents unique challenges for patients and providers largely because the natural course of the untreated disease is not well understood. Because most women diagnosed with DCIS are treated, it is difficult to determine the comparative benefits of different treatment strategies versus active surveillance, meaning systematic followup.
› Verified 4 days ago
Dan F Criswell, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2601 W Elk Ave, Duncan, OK 73533 Phone: 580-251-6644 Fax: 580-251-6645 | |
Krystal Marie Vonfeldt, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2120 W Elk Ave, Duncan, OK 73533 Phone: 580-251-6822 | |
William T Stewart, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1324 N Harville Rd, Duncan, OK 73533 Phone: 580-252-1373 Fax: 580-252-8336 | |
Francis James Mcgouran Iii, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1334 N Harville Rd, Duncan, OK 73533 Phone: 580-255-8564 Fax: 580-255-8640 | |
Demetra G Cox, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1324 N Harville Rd, Duncan, OK 73533 Phone: 580-252-1373 Fax: 580-252-8336 | |
Preston A Waters, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1324 N Harville Rd, Duncan, OK 73533 Phone: 580-252-1373 | |
Dr. Mark Rosekelly, D.O Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 4086 Country Club Rd Ste 2, Duncan, OK 73533 Phone: 580-952-9221 |